Casdin Partners Master Fund, L.P. - Nov 7, 2025 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Signature
Casdin Partners Master Fund, LP, By: Casdin Partners GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member
Stock symbol
LAB
Transactions as of
Nov 7, 2025
Transactions value $
$1,379,318
Form type
4
Date filed
11/12/2025, 07:46 PM
Previous filing
Oct 17, 2025
Next filing
Nov 17, 2025

Reporting Owners (8)

Name Relationship Address Signature Signature date CIK
Casdin Partners Master Fund, L.P. Director, 10%+ Owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK Casdin Partners Master Fund, LP, By: Casdin Partners GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member 2025-11-12 0001534265
Casdin Eli Director, 10%+ Owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK /s/ Eli Casdin, Eli Casdin 2025-11-12 0001534264
Casdin Capital, LLC Director, 10%+ Owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK Casdin Capital LLC, By: /s/ Eli Casdin, Managing Member 2025-11-12 0001534261
Casdin Private Growth Equity Fund II, L.P. Director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK Casdin Private Growth Equity Fund II, L.P., By: Casdin Private Growth Equity Fund II GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member 2025-11-12 0001891102
Casdin Partners GP, LLC Director, 10%+ Owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK Casdin Partners GP LLC, By: /s/ Eli Casdin, Managing Member 2025-11-12 0001534260
Casdin Private Growth Equity Fund II GP, LLC Director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK Casdin Private Growth Equity Fund GP II, LLC, By: /s/ Eli Casdin, Managing Member 2025-11-12 0001919480
Casdin Private Growth Equity Fund, L.P. Director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK Casdin Private Growth Equity Fund, L.P., By: Casdin Private Growth Equity Fund II GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member 2025-11-12 0001823061
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC Director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK Casdin Private Growth Equity Fund GP, LLC, By: /s/ Eli Casdin, Managing Member 2025-11-12 0001864554

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock, $0.001 par value per share Purchase $253K +225K +0.37% $1.12 61.1M Nov 7, 2025 See Footnote F1, F5
transaction LAB Common Stock, $0.001 par value per share Purchase $322K +275K +0.45% $1.17 61.4M Nov 10, 2025 See Footnote F2, F5
transaction LAB Common Stock, $0.001 par value per share Purchase $359K +300K +0.49% $1.20 61.7M Nov 11, 2025 See Footnote F3, F5
transaction LAB Common Stock, $0.001 par value per share Purchase $446K +375K +0.61% $1.19 62.1M Nov 12, 2025 See Footnote F4, F5
holding LAB Common Stock, $0.001 par value per share 2.9M Nov 7, 2025 Direct F6
holding LAB Common Stock, $0.001 par value per share 13.9M Nov 7, 2025 See Footnote F7
holding LAB Common Stock, $0.001 par value per share 2.74M Nov 7, 2025 See Footnote F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1153 to $1.1321. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1688 to $1.1732. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1881 to $1.2053. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1865 to $1.1913. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F5 The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
F6 The securities are owned directly by Eli Casdin.
F7 The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
F8 The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

Remarks:

Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.